MarketCap
Facebook
X
TelegramQuarterly report 2022-Q2
added 08-08-2022
ChemoCentryx DSO Ratio 2011-2026 | CCXI
Annual DSO Ratio ChemoCentryx
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 3.1 | 0.951 | 1.79 | 17.5 | 226 | 964 | - | - | 23.7 | 77.9 | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 964 | 0.951 | 164 |
Quarterly DSO Ratio ChemoCentryx
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | - | 29.2 | 26.7 | 9.12 | 0.44 | 6.24 | 1.18 | 2.5 | 2.96 | 0.37 | 2.61 | 1.6 | 1.52 | 2.24 | 12.2 | 11.7 | 2.54 | 5.66 | 252 | 41.8 | 261 | 522 | 451 | 564 | 648 | 986 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 986 | 0.37 | 154 |
DSO Ratio of other stocks in the Biotechnology industry
| Issuer | DSO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
AgeX Therapeutics
AGE
|
186 | - | -10.17 % | $ 12.2 K |  USA |
 |
I-Mab
IMAB
|
271 | - | - | $ 866 M |  China |
 |
Esperion Therapeutics
ESPR
|
99.7 | $ 3.13 | 0.55 % | $ 651 M | USA |
 |
Exelixis
EXEL
|
43.4 | $ 48.2 | 8.51 % | $ 13.1 B | USA |
 |
Midatech Pharma plc
MTP
|
204 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
84.7 | - | - | $ 40.3 B | USA |
 |
Fortress Biotech
FBIO
|
115 | $ 2.53 | 2.85 % | $ 70.6 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
2.75 K | - | -1.52 % | $ 24.7 M | USA |
 |
Galapagos NV
GLPG
|
56.5 | $ 28.81 | 1.48 % | $ 2.69 B |  Belgium |
 |
Genmab A/S
GMAB
|
97.9 | $ 27.95 | 1.5 % | $ 17.2 B |  Danmark |
 |
Ionis Pharmaceuticals
IONS
|
20.5 | $ 77.0 | 2.33 % | $ 12.3 B | USA |
 |
Kamada Ltd.
KMDA
|
103 | $ 8.29 | 0.91 % | $ 260 M |  Israel |
 |
Kazia Therapeutics Limited
KZIA
|
28.7 | $ 13.58 | 0.97 % | $ 1.8 B |  Australia |
 |
Ligand Pharmaceuticals Incorporated
LGND
|
77.8 | $ 231.58 | -0.31 % | $ 4.24 B | USA |
 |
INmune Bio
INMB
|
19.9 K | $ 1.54 | - | $ 38.1 M | USA |
 |
Liquidia Corporation
LQDA
|
65.5 | $ 41.64 | 3.75 % | $ 3.58 B | USA |
 |
ACADIA Pharmaceuticals
ACAD
|
37.5 | $ 22.58 | 1.03 % | $ 3.74 B | USA |
 |
Mirum Pharmaceuticals
MIRM
|
70.6 | $ 107.36 | 1.46 % | $ 5.39 B | USA |
 |
MannKind Corporation
MNKD
|
26.2 | $ 3.61 | 26.17 % | $ 1.1 B | USA |
 |
Advaxis
ADXS
|
88.1 | - | -9.65 % | $ 45.9 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
28.1 | $ 3.46 | -1.14 % | $ 5.7 M | Israel |
 |
Aeterna Zentaris
AEZS
|
146 | - | 5.93 % | $ 314 M |  Canada |
 |
Aeglea BioTherapeutics
AGLE
|
216 | - | - | $ 1.01 B | USA |
 |
CureVac N.V.
CVAC
|
13.6 | - | - | $ 867 M |  Germany |
 |
Applied Genetic Technologies Corporation
AGTC
|
0.114 | - | - | $ 26.5 M | USA |
 |
AIkido Pharma
AIKI
|
17.9 | - | 1.93 % | $ 17.4 M | USA |
 |
Aptinyx
APTX
|
46.9 | - | -39.0 % | $ 4.57 M | USA |
 |
Albireo Pharma
ALBO
|
14.7 | - | -0.23 % | $ 916 M | USA |
 |
Arcutis Biotherapeutics
ARQT
|
106 | $ 24.0 | 2.46 % | $ 3.05 B | USA |
 |
Alpine Immune Sciences
ALPN
|
154 | - | - | $ 2.17 B | USA |